Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
08
10
2019
accepted:
29
02
2020
pubmed:
26
3
2020
medline:
26
3
2020
entrez:
26
3
2020
Statut:
ppublish
Résumé
The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer molecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor's dominant functional pathway can help allocate effective treatment to appropriate patients. Here we show that BluePrint is a highly precise and highly reproducible test with correlations above 98% based on the generated index and subtype concordance above 99%. Therefore, BluePrint can be used as a robust and reliable tool to identify breast cancer molecular subtypes.
Identifiants
pubmed: 32208353
pii: S1936-5233(19)30501-7
doi: 10.1016/j.tranon.2020.100756
pmc: PMC7097521
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100756Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
PLoS One. 2011 Feb 11;6(2):e17163
pubmed: 21347257
Oncology. 2002;63 Suppl 1:33-8
pubmed: 12422053
Breast Cancer Res Treat. 2013 Jun;139(3):759-67
pubmed: 23756626
Adv Anat Pathol. 2014 Mar;21(2):100-7
pubmed: 24508693
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
Breast Cancer Res. 2017 May 11;19(1):55
pubmed: 28490348
J Mol Diagn. 2014 Mar;16(2):190-7
pubmed: 24378251
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27481837
Nat Rev Clin Oncol. 2010 Jun;7(6):340-7
pubmed: 20440284
Ann Surg Oncol. 2017 Mar;24(3):669-675
pubmed: 27770345
Ann Surg Oncol. 2017 Sep;24(9):2539-2546
pubmed: 28447218
BMC Genomics. 2006 Oct 30;7:278
pubmed: 17074082
J Mol Diagn. 2019 Sep;21(5):808-823
pubmed: 31173928
Ann Surg Oncol. 2016 Oct;23(10):3317-23
pubmed: 27384749
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S23-6
pubmed: 18852851
Clin Cancer Res. 2013 Dec 1;19(23):6371-9
pubmed: 24298067
Lancet Oncol. 2007 Dec;8(12):1079-1087
pubmed: 18042430
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):979-85
pubmed: 17367315
Breast Cancer Res Treat. 2012 May;133(1):37-47
pubmed: 21814749
Breast Cancer Res Treat. 2016 Apr;156(2):279-87
pubmed: 27002507
NPJ Breast Cancer. 2017 Aug 25;3:31
pubmed: 28948212
Breast Cancer Res. 2014 Jun 20;16(3):R65
pubmed: 24951027
Acta Oncol. 2018 Jan;57(1):83-89
pubmed: 29202622
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Per Med. 2013 Nov;10(8):801-811
pubmed: 29776281
BMC Med Genomics. 2016 Aug 20;9(1):54
pubmed: 27542606
Breast Cancer Res Treat. 2018 Jan;167(1):123-131
pubmed: 28929359
Hum Pathol. 2012 Nov;43(11):2070-9
pubmed: 22658277
Mod Pathol. 2015 Jun;28(6):778-86
pubmed: 25698062
J Clin Oncol. 2013 Jan 10;31(2):203-9
pubmed: 23233704
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Semin Diagn Pathol. 2015 Sep;32(5):362-9
pubmed: 25770732
Ann Surg Oncol. 2014 Oct;21(10):3261-7
pubmed: 25099655
Ultrasonography. 2016 Oct;35(4):281-8
pubmed: 27599892
Breast Cancer Res. 2014 May 20;16(3):210
pubmed: 25928070
Int J Cancer. 2013 Aug 15;133(4):929-36
pubmed: 23371464
Arch Pathol Lab Med. 2007 Dec;131(12):1805-16
pubmed: 18081440
NPJ Breast Cancer. 2019 Apr 18;5:15
pubmed: 31016233
Arch Pathol Lab Med. 2019 Dec;143(12):1444-1449
pubmed: 31373514